AMD

Enovix Awarded 15-Year Pioneer Status from Malaysian Investment Development Authority for its High-Volume Manufacturing Facility

Retrieved on: 
Wednesday, March 27, 2024
Growth, BHD, MESDAQ, SAT, Student, Workforce, Income tax, AMD, MIDA, Cleanroom, Silicon

FREMONT, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has been granted 15-year Pioneer Status from the Malaysian Investment Development Authority (MIDA) for manufacturing its batteries in Malaysia.

Key Points: 
  • FREMONT, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it has been granted 15-year Pioneer Status from the Malaysian Investment Development Authority (MIDA) for manufacturing its batteries in Malaysia.
  • Enovix’s high-volume manufacturing facility, Fab2, is located in the Penang Science Park in Penang, Malaysia.
  • “Being awarded Pioneer Status is a monumental milestone for Enovix as we become further established in Malaysia and begin to ramp up manufacturing in our Fab2 facility,” said Ajay Marathe, Chief Operating Officer of Enovix Corporation.
  • With MIDA’s support, I am confident we will scale a sustainable high-volume manufacturing business.”
    For more information on Enovix and its battery technology, please visit enovix.com .

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
Wednesday, March 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board

Retrieved on: 
Monday, April 8, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Faculty, Medical University of Vienna, Part, Patient, Queen's University, Optometry, Queen's University Belfast, CAB, MD, Royal Victoria Hospital, Laborie (company), Medical school, Therapy, Retina, Safety, AMD, Geographic atrophy, Pharmaceutical industry

Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • Aviceda Therapeutics , a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today the formation of its European Clinical Advisory Board (CAB) made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • The Company also announced that Tarek S. Hassan, MD will serve as Chair of the European and US CABs.
  • “We are excited that results from Part 1 of the US Phase 2/3 SIGLEC trial demonstrated functional and anatomic improvement in eyes with GA secondary to AMD after a single injection of AVD-104,” said Mohamed Genead, M.D., Aviceda’s Co-founder and CEO.
  • “With the contributions and support of this esteemed panel—and with Dr. Hassan as its chair—we look forward to bringing our clinical efforts to Europe later this year.”

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

Retrieved on: 
Tuesday, April 9, 2024
Physical Therapy, Technology, Managed Care, Health, Optical, Health Technology, Medical Devices, Photography, Software, Artificial Intelligence, Telemedicine, Virtual Medicine, Research, Diagnosis, Glaucoma, CE, Patient, Hospital, ARVO, IPredict, Paratriathlon, TGA, AMD, Diabetic retinopathy

The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.

Key Points: 
  • The early screening and detection of glaucoma can potentially help prevent the progression to severe glaucoma and save millions of people from blindness.
  • The entire test which includes color retinal imaging and the automated AI-based glaucoma report generation can easily and reliably be completed within 5 minutes.
  • Glaucoma detection offers an overall accuracy of 94.3% for identifying an individual with glaucoma.
  • iPredict’s glaucoma detection model can be used as follows:
    iPredict-glaucoma report will produce which will indicate referable (i.e., early to severe glaucoma) or non-referable glaucoma (not glaucoma).

BlackBerry Announces Collaboration with AMD to Advance Foundational Precision and Control for Robotics Industry

Retrieved on: 
Tuesday, April 9, 2024
Logic, SDP, Embedded, Health care, BlackBerry Limited, Deployment environment, QNX, Software, K26, TSX, Robotics, AMD, BlackBerry, FPGA

NUREMBURG, Germany, April 9, 2024 /PRNewswire/ -- At Embedded World today, BlackBerry Limited (NYSE: BB; TSX: BB) announced a collaboration with AMD designed to revolutionize next-generation robotic systems by enabling new levels of low latency and jitter, and repeatable determinism. Together, the companies will address the critical need for 'hard' real-time capabilities in robotics-focused hardware with an affordable and powerful platform that delivers enhanced performance, reliability, and scalability for robotic systems in industrial and healthcare.

Key Points: 
  • The platform combines BlackBerry® QNX® expertise in real-time foundational software solutions and the QNX® Software Development Platform (SDP) with heterogeneous hardware solutions powered by the AMD Kria™ K26 SOM that features both Arm® and FPGA programmable logic-based architecture.
  • This combination enables sensor fusion, high-performance data processing, real-time control, industrial networking, and reduced latency in robotic applications.
  • "These are crucial attributes for industries carrying out finely tuned operations, such as the fast-growing industries of autonomous mobile robots and surgical robotics.
  • Together with AMD, we are committed to driving technological advancements that address some of these most complex challenges and transform the future of the robotics industry."

Motivair to Exhibit AI-Ready Liquid Cooling Technology at Data Center World

Retrieved on: 
Friday, April 5, 2024
Intel, Science, H100, Corporation, HPC, Research, Big data, Artificial intelligence, Booth, AMD, NVIDIA, Communications satellite

BUFFALO, N.Y., April 5, 2024 /PRNewswire-PRWeb/ -- Motivair Corporation, a global leader and innovator in cooling digital infrastructure and mission-critical applications, will exhibit at Data Center World in Washington, D.C., at Booth 555.

Key Points: 
  • Motivair Corporation, a global leader and innovator in cooling digital infrastructure, artificial intelligence applications, high-wattage processors, and mission-critical applications, will exhibit at Data Center World in Washington, D.C., at Booth 555
    BUFFALO, N.Y., April 5, 2024 /PRNewswire-PRWeb/ -- Motivair Corporation, a global leader and innovator in cooling digital infrastructure and mission-critical applications, will exhibit at Data Center World in Washington, D.C., at Booth 555.
  • The event, April 15-18, is the only global industry event that combines real-world, practitioner, and thought leader expertise with in-depth research and data, and access to a full spectrum of solution providers driving the data center and digital infrastructure industry forward.
  • Stop at booth 555 to learn how Motivair is delivering reliable cooling technology that enables the world to solve complex thermal challenges and advances in technology, business, and science.
  • Attendees can also visit the Motivair booth to see displays of its End-to-End Liquid Cooling Portfolio designed exclusively for HPC, Artificial Intelligence, and Big Data users, including its Coolant Distribution Units (CDUs) and the ChilledDoor®.

Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Retrieved on: 
Friday, March 22, 2024
Retina, Civil service commission, Committee, EMA, European Medicines Agency, Bevacizumab, European, Outlook, Therapy, European Commission, AMD, Marketing, CHMP, Pharmaceutical industry

Outlook Therapeutics is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.

Key Points: 
  • Outlook Therapeutics is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
  • “The CHMP positive opinion for ONS-5010/LYTENAVA™ represents a significant milestone for Outlook Therapeutics and advancement in the treatment of wet AMD in the EU.
  • If approved, an initial ten years of market exclusivity in the European Union (EU) is expected for ONS-5010/LYTENAVA™.
  • The CHMP’s positive opinion supports the grant of marketing authorization by the European Commission (EC) for Outlook Therapeutics’ application for ONS-5010.

TRADING VOLUMES SURGE AS GRANITESHARES SURPASSES $4B AUM

Retrieved on: 
Friday, March 22, 2024
Microsoft, AMD, Growth, ETF, AUM, Tech, Amazon, Financial adviser

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- GraniteShares, an entrepreneurial ETF provider, today announces it has surpassed $4 billion in assets under management (AUM).This milestone is achieved as the GraniteShares suite of ETFs experience rapid growth.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- GraniteShares , an entrepreneurial ETF provider, today announces it has surpassed $4 billion in assets under management (AUM).This milestone is achieved as the GraniteShares suite of ETFs experience rapid growth.
  • "Our core mission has always been to provide investors with innovative and accessible investment solutions,” said Will Rhind, Founder and CEO of GraniteShares.
  • "Investors want to maximize exposure to AI, Tech and Crypto, and at times hedge those positions.
  • Our 2X Short and Leveraged Single Stock offerings allow that with the efficiency of an ETF structure.”
    In response to increasing investor demand for single-stock ETFs, GraniteShares launched 3 new leveraged single stock ETFs on AMD, Amazon and Microsoft.

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Retrieved on: 
Wednesday, March 20, 2024
Joint venture, Patient, Sale, Business analyst, CCHN, IP, Marketing, Research, Mallinckrodt, Absorption, European Economic Area, Gross metropolitan product, Webcast, Asset, Alvogen, Denosumab, Neovascularization, Biosimilar, Macular degeneration, Safety, Food, U.S. FDA, Teva Pharmaceuticals, Revenue, Q3, CES, AMD, FDA, ISK, Administration, Adalimumab, Research and development, Pharmaceutical industry

Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).

Key Points: 
  • Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).
  • Alvotech announced positive top-line results from a pharmacokinetic (PK) study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab).
  • Alvotech announced positive top-line results from a PK study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab.
  • Alvotech will conduct a business update conference call and live webcast on Thursday, March 21, 2024, at 8:00 am ET (12:00 pm GMT).

DVCon U.S. 2024 Announces Stuart Sutherland Best Paper & Best Poster Winners & Conference Highlights

Retrieved on: 
Tuesday, March 19, 2024
Shift, Infineon Technologies, Algorithm, Conference, Nvidia, UVM, Lens, PSS, Working Group, DoubleTree, Verification, Ford Motor Company, Human, Formal, Accellera, Functional, Texas Instruments, Exhibition, Paper, Cadence Design Systems, Poster, AMD, Automotive industry

The 2024 Best Paper and Poster winners, as voted on by attendees, were announced during a reception in the exhibit hall on March 6.

Key Points: 
  • The 2024 Best Paper and Poster winners, as voted on by attendees, were announced during a reception in the exhibit hall on March 6.
  • Overall attendance for DVCon U.S. 2024 was approximately 975, including attendees from 25 exhibiting companies.
  • “It was really an exciting time to be back at DVCon U.S.,” stated Tom Fitzpatrick, DVCon U.S. 2024 General Chair.
  • For the second consecutive year, the Poster Ninja Warrior Session determined the Stuart Sutherland Best Poster Award winners.